Cyclacel regains compliance with nasdaq listing rule following filing of its form 10-q with the sec

Berkeley heights, n.j., nov. 30, 2023 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice from the nasdaq stock market llc (“nasdaq”) indicating that the company has regained compliance with nasdaq listing rule 5250(c)(1) (the “rule”), by filing its quarterly report on form 10-q for the period ended september 30, 2023, on november 29, 2023 with the securities and exchange commission.
CYCC Ratings Summary
CYCC Quant Ranking